Glucocorticoids—all-rounders tackling the versatile players of the immune system

C Strehl, L Ehlers, T Gaber, F Buttgereit - Frontiers in immunology, 2019 - frontiersin.org
Glucocorticoids regulate fundamental processes of the human body and control cellular
functions such as cell metabolism, growth, differentiation, and apoptosis. Moreover …

Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs

G Ruiz-Irastorza, G Bertsias - Rheumatology, 2020 - academic.oup.com
Besides treating acute flares, the management of SLE should aim at preventing organ
damage accrual and drug-associated harms, improving health-related quality of life and …

Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives

C Magro-Checa, EJ Zirkzee, TW Huizinga… - Drugs, 2016 - Springer
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a generic definition referring to a
series of neurological and psychiatric symptoms directly related to systemic lupus …

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

EM Miloslavsky, RP Naden, JWJ Bijlsma… - Annals of the …, 2017 - ard.bmj.com
Objectives To develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-
related morbidity and GC-sparing ability of other therapies. Methods Nineteen experts on …

Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial

A Mathian, M Pha, J Haroche… - Annals of the …, 2020 - ard.bmj.com
Objectives To compare the efficacy to prevent flares of maintenance versus withdrawal of 5
mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent …

Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues

S Porta, A Danza, M Arias Saavedra… - Journal of clinical …, 2020 - mdpi.com
Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid
mechanism of action, low cost, and accessibility have made them one of the mainstays of …

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal …

MF Ugarte-Gil, A Mak, J Leong… - Lupus science & …, 2021 - lupus.bmj.com
Objective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC)
exposure are known to contribute to irreversible organ damage. We aimed to examine the …

The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases

M Ramaswamy, R Tummala, K Streicher… - International Journal of …, 2021 - mdpi.com
Therapeutic success in treating patients with systemic lupus erythematosus (SLE) is limited
by the multivariate disease etiology, multi-organ presentation, systemic involvement, and …

Advances in the management of systemic lupus erythematosus

EF Morand, R Fernandez-Ruiz, A Blazer, TB Niewold - bmj, 2023 - bmj.com
Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can
cause injury in almost every body system. While considered a classic example of …

Treatment targets in SLE: remission and low disease activity state

V Golder, MWP Tsang-A-Sjoe - Rheumatology, 2020 - academic.oup.com
Treat-to-target strategies have changed the approach to management of many chronic
conditions, with improvements in patient outcomes. The key to success of treat to target is …